secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0000950170-25-060563
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint
--------------------------------------------------------------------------------

- Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.
- Cash, equivalents and marketable securities $157.5M as of March 31, 2025; runway into Q2 2026.
- FDA agreed to consider skin FXN concentration as reasonably likely surrogate endpoint for accelerated approval.
- BLA submission planned by year-end 2025; global Phase 3 study to begin mid-2025 with U.S. and international sites.
- Adolescent PK run-in dosing completed; 50 mg OLE and adolescent data expected in September 2025 program update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/0000950170-25-060563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-20250430.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-060563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer